A BIFUNCTIONAL TUMOR ACTIVATED IMMUNOMODULATOR (TRACIR) TARGETING PD-L1 AND CD28 IS A POTENT ENHANCER OF T CELL-MEDIATED ANTI-TUMOR ACTIVITY

被引：0

作者：

DiRaimondo, Thomas ^{[1
]}

Budimir, Natalija ^{[1
]}

Ma, Lina ^{[1
]}

Shenhav, Simon ^{[1
]}

Cicchini, Vanessa ^{[1
]}

Navert, Robert ^{[1
]}

Wu, Hua ^{[1
]}

Jocic, Renee ^{[1
]}

Yu, Cuiling ^{[1
]}

Aceveda, Diane ^{[1
]}

Best, Hannah ^{[1
]}

Prentiss, Clara ^{[1
]}

Muskat, Kai ^{[1
]}

Chang, Jason ^{[1
]}

Dastmalchi, Farhad ^{[1
]}

Roup, Fabrece ^{[1
]}

Caffaro, Carolina ^{[1
]}

Aerni, Hans ^{[1
]}

Godfrey, Wayne ^{[1
]}

Winter, Charles ^{[1
]}

Nasoff, Marc ^{[1
]}

Gibson, Neil ^{[1
]}

Campbell, David ^{[1
]}

Salek-Ardakan, Shahram ^{[1
]}

机构：

[1] Janux Therapeut, San Diego, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.1326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1326

引用

页码：A1377 / A1377

页数：1

共 50 条

[41] SM2275, A tetraspecific, dual EGFR and PD-L1-targeting, conditionally activating co-stimulatory CD28 and simultaneously blocking PD-1/PD-L1 signaling to promoting fully activated T cell killing effects on tumor cells
Lu, Shihao
Liu, Xiaodan
Zhou, Sheila
Song, Wenjing
Geng, Huiqin
Yang, Simin
Zhou, Hong
Xie, Siyao
Wei, Yi
Zhang, Xing
Liang, Yanbin
CANCER RESEARCH, 2024, 84 (06)
[42] Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
Kevin Durgan
Mohamed Ali
Paul Warner
Yvette E. Latchman
Cancer Immunology, Immunotherapy, 2011, 60 : 547 - 558
[43] Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
Durgan, Kevin
Ali, Mohamed
Warner, Paul
Latchman, Yvette E.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) : 547 - 558
[44] Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells
Tomogane, Mako
Sano, Yusuke
Shimizu, Daiki
Shimizu, Teruki
Miyashita, Masatsugu
Toda, Yuki
Hosogi, Shigekuni
Tanaka, Yoshimasa
Kimura, Shinya
Ashihara, Eishi
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 573 : 132 - 139
[45] Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Sun, Bao-Ye
Zhang, Dai
Gan, Wei
Wu, Jing-Fang
Wang, Zhu-Tao
Sun, Guo-Qiang
Zhou, Jian
Fan, Jia
Yi, Yong
Hu, Bo
Zhang, Bo-Heng
Qiu, Shuang-Jian
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (07)
[46] DUAL TARGETING OF INNATE AND ADAPTIVE IMMUNE CHECKPOINTS WITH A PD-L1/SIRPα BISPECIFIC MACROPHAGE ENGAGER TO PROMOTE ANTI-TUMOR ACTIVITY
Sun, Dawei
Lu, Hongtao
Jiang, Haixia
Geng, Yanan
Hu, Jiahui
Ding, Ziqiao
Zhao, Jinfeng
Xu, Xiang
Lu, Wenqiang
Niu, Xiaofeng
Gao, Rui
Wu, Zhihao
Qiu, Quan
Song, Zheng
Qiu, Yangsheng
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1256 - A1256
[47] KNOCKDOWN OF PD-L1 IN MOUSE RENAL CELL CARCINOMA INHIBITS TUMOR GROWTH AND IMPROVE THE ANTI-TUMOR EFFECT OF SUNITINIB
Hara, Takuto
Miyake, Hideaki
Nakano, Yuzo
Fujisawa, Masato
JOURNAL OF UROLOGY, 2020, 203 : E241 - E242
[48] Knockdown of PD-L1 in mouse renal cell carcinoma inhibits tumor growth and improve the anti-tumor effect of Sunitinib
Hara, T.
Miyake, H.
Fujisawa, M.
INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 193 - 193
[49] YTHDF2 promotes tumor immune evasion by inhibiting CD8+T cell-mediated anti-tumor immunity
Ma, Shoubao
Xiao, Sai
Caligiuri, Michael
Yu, Jianhua
JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
[50] PD-L1 ligation enhances NK cell anti-tumor function by inducing a metabolic shift
Srpan, Katja
Lupo, Kyle
Hsu, Katharine
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 516 - 516

← 1 2 3 4 5 →